PDCD1 and melanoma: Given these substantial improvements in outcomes for patients with metastatic disease, ICIs were quickly investigated in the resected stage III melanoma setting where adjuvant anti-PD-1 with pembrolizumab was shown to reduce recurrence by approximately 40% compared to placebo (5).